BLIS Technologies Ltd BLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- NZD 0.02
- Day Range
- NZD 0.02–0.02
- 52-Week Range
- NZD 0.01–0.03
- Bid/Ask
- NZD 0.02 / NZD 0.02
- Market Cap
- NZD 21.65 Mil
- Volume/Avg
- 137,678 / 222,409
Key Statistics
- Price/Earnings (Normalized)
- 8,500.00
- Price/Sales
- 2.17
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets two strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 both of which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 47
- Website
- https://www.blis.co.nz
Valuation
|
Metric
|
BLT
|
|---|---|
Price/Earnings (Normalized) | 8,500.00 |
Price/Book Value | 2.13 |
Price/Sales | 2.17 |
Price/Cash Flow | — |
Price/Earnings
BLT
Financial Strength
|
Metric
|
BLT
|
|---|---|
Quick Ratio | 5.91 |
Current Ratio | 6.59 |
Interest Coverage | −16.89 |
Quick Ratio
BLT
Profitability
|
Metric
|
BLT
|
|---|---|
Return on Assets (Normalized) | 0.44% |
Return on Equity (Normalized) | 0.51% |
Return on Invested Capital (Normalized) | −2.17% |
Return on Assets
BLT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pjsnbmtdt | Ygwnr | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vmcwmzxn | Nmhwhlp | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wbqysyz | Zkqyrh | $97.8 Bil | |
MRNA
| Moderna Inc | Hmdpxzly | Hqtd | $38.8 Bil | |
ARGX
| argenx SE ADR | Wzmmknp | Xspr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gpstrgnj | Llcyc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ztrnyryp | Fcjvxy | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Phkzyqxyv | Xysjkn | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wmkprqysyz | Zdsfjy | $12.5 Bil | |
INCY
| Incyte Corp | Cdjljnkw | Xwbzprn | $11.5 Bil |